What new technologies will emerge in the field of diabetes in 2017?

[market analysis of chinapharma.com] what new technologies will appear in the field of diabetes in 2017? Medtronic released the historical hybrid closed-loop system in spring 2016, which ushered in a new era of artificial pancreas technology And that's just one of the few exciting developments we're looking forward to this year (what new technologies will emerge in the field of diabetes in 2017? Source: Baidu pictures) in order to predict other developments in 2017, we have been listening to financial conference calls and communicating with corporate executives, insiders and public relations teams These will be edited in the next report Minimed670g: in September 2016, after FDA review, minimed670g will be the world's system that can adjust insulin delivery according to CGM (continuous blood glucose monitoring) value, which can make users as close as possible to the target blood glucose value of 120mg / dl The device itself will be equipped with vertical design layout and color display However, the device does not support data sharing Minimed670g uses a new guardian3cgm sensor, and Medtronic has improved its accuracy and reliability The system is directly linked with Bayer contourlink2.4 finger acupuncture instrument In 2016, ascendia blood glucose instrument introduced Bayer contourlink2.4 finger acupuncture instrument, allowing the instrument to remotely control the use of insulin pills When it comes to the release time of 670g, Medtronic only says "early 2017." Tandem's automated insulin delivery device (AID): the manufacturer of the insulin pump plans to release a closed-loop system by the end of 2017 The feature of the device is the prediction of hypoglycemia pause (PLGS), which in many ways reflects what the medt system needs first The production line of tandem diabetes nursing instrument shows the current situation and the development plan of the company in the next few years Other artificial pancreas systems: Yes, we are also looking at many other closed-loop system projects - Bigfoot, Ilet, etc - but we do not expect these to be realized in 2017, and we still need to continue the research and experiment (R & D) link In addition to the closed-loop project (or cross project, depending on who you ask), Medtronic tells us that they are working on a "holistic" approach that integrates CGM, mobile apps and data analysis A spokesman, pamleese, said it was probably a project to look forward to in 2017 Independent CGM: "it will be our step to develop an independently operated CGM system The independent CGM system can provide users with insulin injection according to the real-time data sent by the sensors on their smartphones The system also has the function of text message warning, so that the guardian can receive the alarm of high or low blood sugar content through the mobile phone In addition, the system will also have the option to automatically upload daily sensor information to CareLink professional software, allowing health service providers to obtain useful data, provide care services to people with diabetes and adjust treatment methods as needed This will provide clinicians with more point data on the change trend of blood glucose content, help doctors see fresh diseases, and help patients with diabetes optimize treatment methods " Sugar.iq application: "the cognitive app we developed with IBM Watson Medical Co., Ltd is based on this kind of data This app can help detect important diseases and blood sugar trends of diabetic patients Sugar.iq application will use IBM Watson analysis method to analyze data characteristics and provide real-time, operable and personalized cognition In this way, people with diabetes can enjoy life more freely This app will provide personal guidance, and only through the app platform related diabetes data and observation in daily diabetes management to provide awareness and management of the condition " We can't set a specific timetable for any of the new tools, but we hope to hear more about them at the ADA annual meeting in June Dexcom is a leader in innovative products and has been working on a small number of new tools Although Deloitte has submitted three tools to FDA, we still look forward to the fourth tool to be submitted to FDA in the next few months: 1 Touch screen receiver: it is positioned as the upgraded version of the current Deloitte receiver, and will improve the durability and speaker problems 2 New one button insertion device: expected to be released in the middle of the year According to the prototype pictures we have seen, the device should be similar to the enlite sensor insertion device of Medtronic, which can be operated by one hand 3 Small size G5 transmitter: it will be more compact than the current G6, even smaller than the previous G4 model 4 New generation G6 sensor: due to the exciting dose statement from FDA received by Deccan in December, the plan of Deccan's new sensor in 2016 is delayed, but the plan is expected to be launched in early 2017 and may be released by the end of the year G6 will be a real leap of CGM technology, extending the current 7-day wear period to 10 days, reducing the daily correction times from 2 to 1, and improving the accuracy and reliability This shows the rapid development of FDA in diabetes technology in recent years, and we are optimistic at present! Abbott hopes that Abbott's novel free style Libre instantaneous blood glucose detector technology will enter the U.S market in 2017 The system combines fingertip pricking blood test and CGM (continuous blood glucose monitoring) with one-point noninvasive technology In other words, the system consists of a small white prototype sensor on the skin and a "receiver" similar to a hand-held PDM Users can move the sensor and obtain the blood glucose index through wireless connection You can use it frequently or according to your own wishes, as an alternative to saving expensive test paper, and as you wish, you do not need to run a complete set of CGM equipment In early 2016, Abbott Pharma received FDA's license for Libre clinic professional edition, and Abbott Pharma has completed the family personal edition Therefore, the issue is only a matter of time I think patients will be very excited about this! Johnson & Johnson vibeplus: vibeplus is the new name of Johnson's next generation blood glucose pump, because onetouch has removed animas from its name and seems to be merging all products of onetouch brand series In December 2016, FDA approved the product only six months after it was submitted Several main features: the product still retains 200 insulin agents (consistent with the previous model), waterproof and applicable to glooko diasend data sharing software The product does not have the same instrument remote control as Ping, and cannot be upgraded at home But JNJ explained to us that "remote update capability is a consideration for our future products." Vibeplus comes in five colors (blue, black, silver, pink and lime green) and eight personalized skins A Johnson & Johnson onetouch spokesperson told us that they are evaluating the release time and the features provided after upgrading the system Onetouchvia: Yes, after we proposed onetouchvia (formerly calibrafiness) in 2016, onetouchvia became a wait-and-see project It is a pill only, wearable insulin delivery device It has very stable performance and can be worn for up to three days It has 200 fast acting insulin pills, and if you press the button on the right side of the patch, you can allow PWD to consume two units of insulin pills without the need for independent control units This patch blood glucose pump replacement was approved by the FDA for the treatment of type T1 and T2 diabetes in 2010 In 2012, jnjonetouch purchased the technology But the technology has never been used in practice and seems to have been forgotten Until now! If jnjonetouch can put the product's distribution plan in order, we will be looking forward to seeing this product in 2017 Omnipod will hold the technology part of the ADA annual meeting in the summer of 2017 We are looking forward to seeing the new omnipod PDM (called "dash,") During "investor day" in November last year, silver Hewitt detailed plans for the launch of the new Bluetooth controlled omnipod at the end of this year Although the pipeline free insulin pump retains the same waveform factor, it will establish a low consumption Bluetooth wireless function, allowing connection with the new color touch screen PDM This also allows for a connection to the BT fingertip blood pricking device, however, which means that the next-generation omnipoddash, like the current insulin pump, will not be equipped with a freestyle blood glucose device This is an important defect for the preference of comprehensive equipment users It is gratifying that the new BT insulin pump and PDM will be directly connected to the smartphone app Users can track the insulin content (iob) on the smartphone display screen and the new PDM, and obtain the characteristic data such as dosage record and CGM data To record carbohydrate content, the new PDM is equipped with a complete food database You can manually access BG or use the beautiful touch wheel to choose to access other data The new touch screen will be built on Android The app's data will be locked, so it will not be interfered by other cellular data Thanks to the new x2 insulin pump, tandem has now been able to provide remote users with the ability to update the devices they use at home (without having to upgrade or sell like the current D device model) This technology can realize the combination of the system and G5, which is the project that tandem will submit to FDA, and is expected to be released in mid-2017 Their integrated system also includes the ability to predict hypoglycemia, and existing users can update their devices and use them once their functions are verified Intelligent insulin delivery technology: in the past few months, we have reported two innovations released by Beckton Dickinson: patch pump for type 2: This product is completely disposable, can be worn for three days, and provides both basic dose and single dose The details of the product are not clear, but it is expected to be seen at the 2017 annual financial meeting Smart tip technology: this also means Bluetooth tip technology allows dose data sharing, as BD is committed to bringing more diabetes interoperability management to its product portfolio The tip technology being developed is suitable for all types of insulin pens In this regard, inpen: in July 2016, FDA approved the product, which can appear at any time in 2017 The following are the features of the product mentioned in our July 2015 report: the product base includes computer chip technology, including Bluetooth Le wireless function, refillable Lilly or novo insulin inner package (the only two insulin inner packages available in the United States) The pen contains a temperature sensor If the temperature of the pen drops below the freezing point or rises above the body temperature, the app alarm can be triggered to ensure that the insulin is intact Collect user information and send it to the app The app contains a dose calculator, which can calculate the insulin content (iob) in real time The smartphone app also allows users to set meals